CoChat
Cited by 182

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

Open access
Mayer, Katharina A., Schrezenmeier, Eva, Diebold, Matthias, Halloran, Philip F., Schatzl, Martina, Schranz, Sabine, Haindl, Susanne, Kasbohm, Silke, Kainz, Alexander, Eskandary, Farsad, Doberer, Konstantin, Patel, Uptal D., Dudani, Jaideep S., Regele, Heinz, Kozakowski, Nicolas, Kläger, Johannes, Boxhammer, Rainer, Amann, Kerstin, Puchhammer-Stöckl, Elisabeth, Vietzen, Hannes, Beck, Julia, Schütz, Ekkehard, Akifova, Aylin, Firbas, Christa, Gilbert, Houston N., Osmanodja, Bilgin, Halleck, Fabian, Jilma, Bernd, Budde, Klemens, Böhmig, Georg A. · 2024 · New England Journal of Medicine

Abstract

BACKGROUND: Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic option. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned patients with antibody-mediated rejection that had occurred at least 180 days after transplantation to receive nine infusions of the CD38 monoclonal antibody felzartamab (at a dose of 16 mg per kilogram of body weight) or placebo for 6 months, followed by a 6-month observation period. The primary outcome was the safety and side-effect profile of felzartamab. Key secondary outcomes were renal-biopsy results at 24 and 52 weeks, donor-specific antibody levels, peripheral NK-cell counts, and donor-derived cell-free DNA levels. RESULTS: A total of 22 patients underwent randomization (11 to receive felzartamab and 11 to receive placebo). The median time from transplantation until trial inclusion was 9 years. Mild or moderate infusion reactions occurred in 8 patients in the felzartamab group. Serious adverse events occurred in 1 patient in the felzartamab group and in 4 patients in the placebo group; graft loss occurred in 1 patient in the placebo group. At week 24, resolution of morphologic antibody-mediated rejection was more frequent with felzartamab (in 9 of 11 patients [82%]) than with placebo (in 2 of 10 patients [20%]), for a difference of 62 percentage points (95% confidence interval [CI], 19 to 100) and a risk ratio of 0.23 (95% confidence interval [CI], 0.06 to 0.83). The median microvascular inflammation score was lower in the felzartamab group than in the placebo group (0 vs. 2.5), for a mean difference of -1.95 (95% CI, -2.97 to -0.92). Also lower was a molecular score reflecting the probability of antibody-mediated rejection (0.17 vs. 0.77) and the level of donor-derived cell-free DNA (0.31% vs. 0.82%). At week 52, the recurrence of antibody-mediated rejection was reported in 3 of 9 patients who had a response to felzartamab, with an increase in molecular activity and biomarker levels toward baseline levels. CONCLUSIONS: Felzartamab had acceptable safety and side-effect profiles in patients with antibody-mediated rejection. (Funded by MorphoSys and Human Immunology Biosciences; ClinicalTrials.gov number, NCT05021484; and EUDRACT number, 2021-000545-40.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2400763

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Metadata

Authors
Mayer, K. A., Schrezenmeier, E., Diebold, M., Halloran, P. F., Schatzl, M., Schranz, S., Haindl, S., Kasbohm, S., Kainz, A., Eskandary, F., Doberer, K., Patel, U. D., Dudani, J. S., Regele, H., Kozakowski, N., Kläger, J., Boxhammer, R., Amann, K., Puchhammer-Stöckl, E., Vietzen, H., Beck, J., Schütz, E., Akifova, A., Firbas, C., Gilbert, H. N., Osmanodja, B., Halleck, F., Jilma, B., Budde, K., & Böhmig, G. A.
Venue
New England Journal of Medicine
Published
2024-07-11
Volume
391
Issue
2
Pages
122-132
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4399012950
Cited by
182
References
3
FWCI
77.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. https://app.cochat.ai/papers/10.1056/nejmoa2400763
The paper
Mayer, K. A., Schrezenmeier, E., Diebold, M., Halloran, P. F., Schatzl, M., Schranz, S., Haindl, S., Kasbohm, S., Kainz, A., Eskandary, F., Doberer, K., Patel, U. D., Dudani, J. S., Regele, H., Kozakowski, N., Kläger, J., Boxhammer, R., Amann, K., Puchhammer-Stöckl, E., . . . Böhmig, G. A. (2024). A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2400763

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.